Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Evaluation of Gut Permeability and Difficult-to-treat Psoriatic Arthritis

FY 2023-24

Summary
Psoriatic arthritis (PsA) is a form of inflammatory arthritis that affects approximately 300,000 Canadians. It is a disease that affects the skin and joints, among other areas of the body. PsA may lead to joint destruction, disability, and decreased quality of life for patients. Despite the availability of targeted immunomodulatory therapies, many patients are unresponsive and are difficult-to-treat (D2T). Co-existing conditions like metabolic syndrome and obesity have been associated with diminished response or resistance to treatment. Weight loss has led to improvement in disease status in obese PsA patients. Furthermore, PsA patients may have abnormal gut barrier function (gut permeability) and abnormal gut microorganisms (microbiome). These findings suggest that response to PsA treatment may be linked to the gut microbiome and gut permeability, which may be important contributing factors to D2T PsA. The proposed research project aims to describe the characteristics of all D2T PsA patients enrolled in the Schroeder Arthritis Institute’s PsA cohort since the year 2000, compared to PsA patients in remission on treatment with targeted immunomodulatory therapies. Secondly, the study will evaluate whether there is an association between gut permeability and D2T PsA by comparing gut permeability in a subset of patients who are D2T and those who are in remission. This study will be the first to describe the clinical and demographic characteristics of D2T PsA patients and determine the association between gut permeability and D2T PsA, using formal D2T definition. Results will inform further studies to assess the role of gut microbiome in PsA treatment response/remission and subsequent design of clinical trials to improve disease outcomes for D2T PsA patients.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
505944
Name
Chronis Nicholas J
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Evaluation of Gut Permeability and Difficult-to-treat Psoriatic Arthritis
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Disease Activity; Gut Dysbiosis; Gut Microbiome; Gut Permeability; Inflammation; Metabolic Syndrome; Metabolome; Obesity; Psoriatic Arthritis; Treatment Resistance
Abstract
Psoriatic arthritis (PsA) is a form of inflammatory arthritis that affects approximately 300,000 Canadians. It is a disease that affects the skin and joints, among other areas of the body. PsA may lead to joint destruction, disability, and decreased quality of life for patients. Despite the availability of targeted immunomodulatory therapies, many patients are unresponsive and are difficult-to-treat (D2T). Co-existing conditions like metabolic syndrome and obesity have been associated with diminished response or resistance to treatment. Weight loss has led to improvement in disease status in obese PsA patients. Furthermore, PsA patients may have abnormal gut barrier function (gut permeability) and abnormal gut microorganisms (microbiome). These findings suggest that response to PsA treatment may be linked to the gut microbiome and gut permeability, which may be important contributing factors to D2T PsA. The proposed research project aims to describe the characteristics of all D2T PsA patients enrolled in the Schroeder Arthritis Institute’s PsA cohort since the year 2000, compared to PsA patients in remission on treatment with targeted immunomodulatory therapies. Secondly, the study will evaluate whether there is an association between gut permeability and D2T PsA by comparing gut permeability in a subset of patients who are D2T and those who are in remission. This study will be the first to describe the clinical and demographic characteristics of D2T PsA patients and determine the association between gut permeability and D2T PsA, using formal D2T definition. Results will inform further studies to assess the role of gut microbiome in PsA treatment response/remission and subsequent design of clinical trials to improve disease outcomes for D2T PsA patients.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Chronis, Nicholas J
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~